切除可能境界膵癌に対する術前FIRINOX療法－パイロット研究

基本情報

NCT ID

NCT02148549

ステータス

完了

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

10

治験依頼者名

Wakayama Medical University

概要

FOLFIRINOX regimen was recently presented at an international oncology meeting and represents a new standard regimen in the treatment of metastatic pancreatic cancer. FOLFIRINOX is one of the high response rate treatment regimen , the investigators considered as a promising treatment as neoadjuvant chemotherapy . On the other hand , incidences of grade 3 or 4 neutropenia , febrile neutropenia and diarrhea were significantly higher in the FOLFIRINOX group compared with gemcitabine group. Therefore, it was decided to consider the balance of safety and efficacy as a preoperative chemotherapy, the investigators use the FIRINOX regimen by eliminating LV and bolus 5-FU, and irinotecan reduced to 150mg/m2 of 180mg/m2 from FOLFIRINOX regimen

対象疾患

介入

依頼者（Sponsor）

実施施設 (8)